Chemotherapy News and Research

Latest Chemotherapy News and Research

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

Nanoflower-treated stem cells deliver healthier mitochondria to stressed cells

This study shows that vacancy-engineered MoS₂ nanoflowers drive mitochondrial biogenesis in human mesenchymal stem cells by activating SIRT1–PGC-1α signaling and reducing oxidative stress. These treated cells transfer more functional mitochondria to injured recipient cells, restoring energy metabolism and redox balance in multiple in vitro models.

9 Dec 2025

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumors.

9 Dec 2025

Trump’s idea for health accounts has been tried. Millions of patients have ended up in debt.

Sarah Monroe once had a relatively comfortable middle-class life. She and her family lived in a neatly landscaped neighborhood near Cleveland. They had a six-figure income and health insurance. Then, four years ago, when Monroe was pregnant with twin girls, something started to feel off.

9 Dec 2025

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare and aggressive form of blood cancer called T-cell acute lymphoblastic leukemia (T-ALL).

8 Dec 2025

Powerful prognostic marker could enable early identification of high-risk cancer patients

Aggressive T-cell lymphoma is a rare and devastating form of blood cancer with a very low five-year survival rate.

8 Dec 2025

Combination therapy may boost survival for people with aggressive lymphoma

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.

8 Dec 2025

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

8 Dec 2025

Timing of genetic mutation dictates childhood leukemia aggressiveness

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same leukemia-causing gene mutation can have dramatically different outcomes: it depends on when in development the mutation first occurs.

8 Dec 2025

A slow-growing, bone-covered, noncancerous mass named as ossifying spindled and epithelioid tumor

It's not often that a pathologist gets to make a diagnosis that works for the patient by preventing treatment from occurring.

8 Dec 2025

Receiving immunotherapy earlier in the day may improve survival in cancer patients

Receiving anticancer immunotherapy earlier in the day may help individuals with cancer live longer. That's according to a study published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

8 Dec 2025

New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an aggressive form of brain cancer, live longer.

8 Dec 2025

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study.

7 Dec 2025

Virtual diet and exercise program shows promise in reducing lymphoma treatment side effects

Patients undergoing treatment for lymphoma often experience adverse side effects that can be so severe that they stop or slow treatment.

7 Dec 2025

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy.

7 Dec 2025

New trial shows major survival gains with epcoritamab added to standard R2 therapy

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone.

7 Dec 2025

Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received chemotherapy-based conditioning or total body irradiation (TBI), the standard conditioning regimen used before hematopoietic cell transplantation.

7 Dec 2025

Many families of children with leukemia face significant financial hardship during treatment

Nearly a third of families with children receiving chemotherapy for acute lymphoblastic leukemia (ALL) – the most common pediatric cancer – develop serious financial difficulties during their child's treatment, including losing 25% or more of their household income and struggling to cover the costs of basic living expenses such as housing, food, and utilities.

7 Dec 2025

Black patients with AML experience earlier onset and poorer outcomes

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more than 20% more likely to die of any cause, according to an analysis of data conducted over a 34-year period and supported by the National Cancer Institute (NCI) is a component of the U.S. National Institutes of Health.

7 Dec 2025

New evidence shows hematopoietic cell transplantation offers durable relief for sickle cell disease

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease symptoms and low rates of severe side effects or complications years after their procedure, according to a new study.

7 Dec 2025

Chemotherapy News and Research

Latest Chemotherapy News and Research

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

Nanoflower-treated stem cells deliver healthier mitochondria to stressed cells

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

Trump’s idea for health accounts has been tried. Millions of patients have ended up in debt.

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

Powerful prognostic marker could enable early identification of high-risk cancer patients

Combination therapy may boost survival for people with aggressive lymphoma

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Timing of genetic mutation dictates childhood leukemia aggressiveness

A slow-growing, bone-covered, noncancerous mass named as ossifying spindled and epithelioid tumor

Receiving immunotherapy earlier in the day may improve survival in cancer patients

New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

Virtual diet and exercise program shows promise in reducing lymphoma treatment side effects

Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients

New trial shows major survival gains with epcoritamab added to standard R2 therapy

Chemotherapy-based conditioning matches outcomes of total body irradiation for MRD-negative B-ALL

Many families of children with leukemia face significant financial hardship during treatment

Black patients with AML experience earlier onset and poorer outcomes

New evidence shows hematopoietic cell transplantation offers durable relief for sickle cell disease

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in